| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5972916 | HALEON US HOLDINGS | Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine |
Jul, 2017
(6 years ago) | |
Excedrin (Migraine Relief) is owned by Haleon Us Holdings.
Excedrin (Migraine Relief) contains Acetaminophen; Aspirin; Caffeine.
Excedrin (Migraine Relief) has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Excedrin (Migraine Relief) are:
- US5972916
Excedrin (Migraine Relief) was authorised for market use on 14 January, 1998.
Excedrin (Migraine Relief) is available in tablet;oral dosage forms.
Excedrin (Migraine Relief) can be used as treating migraine pain and one or more of a cluster of symptoms characteristic of a migraine attack symptoms being selected from photophobia, phonophobia nausea and functional disability.
The generics of Excedrin (Migraine Relief) are possible to be released after 14 July, 2017.
Drugs and Companies using ACETAMINOPHEN; ASPIRIN; CAFFEINE ingredient
Market Authorisation Date: 14 January, 1998
Treatment: Treating migraine pain and one or more of a cluster of symptoms characteristic of a migraine attack symptoms being selected from photophobia, phonophobia nausea and functional disability
Dosage: TABLET;ORAL
EXCEDRIN (MIGRAINE RELIEF) family patents
